Introduction {#s1}
============

Hepatitis C virus (HCV) is a single-stranded RNA virus belonging to the Flaviviridae family. Approximately 64--103 million people are infected with HCV worldwide, making HCV one of the major causes of chronic liver disease.[@b1] Acute infection may resolve spontaneously in 15%--45% of cases, but the remaining 55%--85% of infected individuals (75%--85% according to serologic surveys) fail to clear the virus and become chronically infected.[@b1],[@b2] In a significant number of patients, chronic hepatitis C (CHC) will progress to cirrhosis and hepatocellular carcinoma (HCC), which represent the end-stage HCV-related liver disease, and are among the leading causes for liver transplantation in the Western world.[@b2] Approximately 350,000 to 500,000 people die each year from hepatitis C-related liver diseases around the world.[@b1]

The primary host cells for HCV are hepatocytes, although replication may also occur in other cell types, such as peripheral blood mononuclear cells and B and T lymphocytes.[@b3],[@b4] HCV interferes with the hepatic lipid metabolism throughout its life cycle. Viral entry into hepatocytes occurs following its binding to low-density lipoprotein receptors.[@b5],[@b6] Once internalized, HCV interferes with the host lipid metabolism for its replication and assembly, which consequently leads to hepatic steatosis. Finally, the virus is released from the hepatocyte via the very low-density lipoprotein secretion pathway.[@b7]

Hepatic steatosis is a condition in which there is excessive accumulation of triglycerides within the hepatocytes. The most common causes are alcohol consumption (alcoholic fatty liver disease) and insulin resistance (IR) within the metabolic syndrome (MS) (non-alcoholic fatty liver disease - NAFLD), but other causes, including malnutrition, total parenteral nutrition, severe weight loss, gastrointestinal bypasses, some inherited metabolic conditions (e.g., abetalipoproteinemia), glycogen storage diseases, lipodystrophy, alpha 1-antitrypsin deficiency, pregnancy, drugs and toxins, as well as human immunodeficiency virus (HIV) and chronic HCV infection, are also responsible for a number of cases.

NAFLD is one of the most common causes of chronic liver disease in the Western world. It represents a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), where steatosis is associated with hepatic inflammation and various degrees of fibrosis and cirrhosis, which develops as a consequence of long-standing NASH.[@b8] NAFLD is estimated to affect around 25%--30% of the general population, while NASH is reported in 2%--3% of the population.[@b9]

Strong epidemiological, biochemical, and therapeutic evidence implicate IR as the primary pathophysiological derangement and the key mechanism leading to hepatic steatosis. Indeed, NAFLD is regarded as a hepatic manifestation of the MS.

MS represents a combination of well-known and established cardiovascular disease related risk factors. Multiple definitions of MS exist with several revisions; and although criteria differ, the essential components of MS include insulin resistance/hyperglycemia, dyslipidemia, hypertension, and visceral obesity.[@b10]--[@b14] These factors have a tendency of clustering together, and individuals with MS have a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality.[@b15]

Hepatic steatosis in CHC infection results from the combination of several host and viral factors that directly interfere with lipid metabolism within the hepatocytes or cause different metabolic derangements through IR. Host factors include the before mentioned components of MS, such as obesity and type 2 diabetes mellitus (T2DM); but also include alcohol consumption, medication use, and genetic predisposition (e.g., interleukin (IL) 28B polymorphism).[@b16],[@b17] Viral factors include genotype (genotype 3 causing the most pronounced steatosis), HCV RNA load, and gene mutations.[@b16]--[@b18]

HCV and insulin resistance {#s2}
==========================

Glucose metabolism impairment, development of IR, and T2DM can often be found accompanying CHC and is commonly measured using the homeostatic model assessment (HOMA) index. Euglycemic insulin clamp studies have shown that IR in CHC has both a hepatic and a peripheral component and induces an array of host metabolic changes.[@b19],[@b20] Besides promoting steatosis and fibrosis progression, the presence of IR has been shown to impair treatement response and, vice-versa, regress following successful treatment outcome.

Several studies have assessed IR in hepatitis C patients before and after interferon therapy. Petit *et al*. report that IR in nondiabetic HCV-infected patients was related to grading of liver fibrosis and may occur early in the course of HCV infection.[@b21] In a study including 260 HCV-infected subjects, Hui *et al*. found that HCV may induce IR irrespective of the severity of liver disease and that genotype 3 had a significantly lower HOMA-IR than other genotypes.[@b22] On the other hand, another study found that median HOMA-IR was significantly higher in patients with genotype 1 related steatosis than in those with genotype 3 related steatosis.[@b23] Irrespective of the genotype, higher HCV RNA levels were associated with the presence of IR and, accordingly, the severity of hepatic steatosis,[@b24],[@b25] where treatment and clearance of HCV improved IR.[@b26]--[@b28] Regarding the impact of HCV infection on the development of T2DM, a meta-analysis of 34 studies found a positive correlation between HCV infection and increased risk of T2DM in comparison to the general population in both retrospective and prospective studies.[@b29] Studies investigating the association between HCV and IR, and their key findings, are summarized in [Table 1](#t01){ref-type="table"}.

###### The association between hepatitis C virus (HCV) and insulin resistance

  Methods/Study population                                                                                               Findings and conclusions                                                                                                                                                            Author
  ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------
  15 CHC patients assessed before and after IFNα therapy                                                                 Glucose tolerance improved after IFNα treatment                                                                                                                                     Tanaka *et al*.,[@b30] 1997
  13 nondiabetic CHC patients before and after IFNα therapy                                                              HCV-induced liver injury related to deterioration of insulin sensitivity and impaired glucose homeostasis                                                                           Konrad *et al*.,[@b31] 2000
  103 nondiabetic CHC patients                                                                                           IR related to grading of liver fibrosis and occurred at an early stage of HCV infection                                                                                             Petit *et al*.,[@b21] 2001
  160 patients with CHC                                                                                                  Circulating insulin levels increased with fibrosis in overweight patients with CHC                                                                                                  Hickman *et al*.,[@b32] 2003
  260 CHC patients                                                                                                       HCV may induce IR irrespective of the severity of liver disease. Genotype 3 associated with lower HOMA-IR                                                                           Hui *et al*.,[@b22] 2003
  141 nondiabetic CHC patients                                                                                           IR was significantly higher in patients with genotype 1 related steatosis than in genotype 3                                                                                        Fartoux *et al*.,[@b23] 2005
  159 patients with CHC genotype 1 (113) and non-1 genotype (46) treated with IFN/RBV                                    SVR independently related to genotype, IR, and fibrosis                                                                                                                             Romero-Gómez *et al*.,[@b33] 2005
  90 patients with CHC and 90 with NAFLD                                                                                 Basal and postload IR were lower in CHC patients than in NAFLD                                                                                                                      Svegliati-Baroni *et al*.,[@b34] 2007
  17 CHC patients not receiving pharmacological treatment                                                                70% overweight or obese, 77% presented with IR                                                                                                                                      Vázquez-Vandyck *et al*.,[@b35] 2007
  89 CHC patients receiving IFNα or IFNα/RBV                                                                             HCV clearance improved IR, β-cell function, and hepatic IRS1&2 expression                                                                                                           Kawaguchi *et al*.,[@b26] 2007
  232 CHC and 56 HCV eradicated patients                                                                                 CHC patients had higher prevalence of T2DM and IR                                                                                                                                   Imazeki *et al*.,[@b36] 2008
  162 CHC patients assessed before treatment                                                                             Higher HCV RNA levels associated with the presence of IR and hepatic steatosis                                                                                                      Hsu *et al*.,[@b24] 2008
  346 untreated, nondiabetic CHC patients with genotype 1 or 3                                                           HOMA-IR rather than steatosis was independently associated with fibrosis regardless of genotype                                                                                     Cua *et al*.,[@b37] 2008
  201 CHC patients with genotype 1                                                                                       IR and overt diabetes were related to advanced fibrosis, regardless of steatosis                                                                                                    Petta *et al*.,[@b38] 2008
  82 CHC patients treated with either IFN/RBV (59) or pegylated-IFN/RBV (23)                                             Patients with lower HOMA-IR were more likely to achieve SVR                                                                                                                         Poustchi *et al*.,[@b39] 2008
  34 postliver transplant patients evaluated (14 HCV positive and 20 HCV negative)                                       Higher IR in the HCV positive group. Higher HCV RNA levels were associated with higher HOMA-IR                                                                                      Delgado-Borrego *et al*.,[@b40] 2008
  500 CHC patients                                                                                                       IR was present in 32.4% of nondiabetic CHC, associated with genotypes 1 and 4 as well as high HCV RNA levels. Fibrosis was associated with IR independent from steatosis            Moucari *et al*.,[@b25] 2008
  Meta-analysis including 34 studies of HCV infected patients                                                            T2DM risk was higher in HCV-infected in both retrospective and prospective studies                                                                                                  White *et al*.,[@b29] 2008
  275 nondiabetic treatment-naïve CHC patients                                                                           IR was increased in 37% of patients, contributing to fibrosis progression, and was more prevalent in obese patients with steatosis. No connections with genotype or viremia.        Tsochatzis *et al*.,[@b41] 2009
  28 CHC patients treated with pegylated-IFNα2a/RBV                                                                      Disappearance of HCV RNA at 6 months after treatment independently reduced IR                                                                                                       Kim *et al*.,[@b27] 2009
  38 CHC patients and healthy controls                                                                                   IR was positively correlated with HCV infection and liver fibrosis                                                                                                                  Mohamed *et al*.,[@b42] 2009
  14 patients with CHC (without MS) and 7 healthy controls                                                               HCV infection was associated with peripheral and hepatic IR                                                                                                                         Vanni *et al*.,[@b19] 2009
  170 HCV mono-infected nad 170 HIV/HCV co-infected patients                                                             IR was associated with liver fibrosis and steatosis in HCV mono-infected.                                                                                                           Halfon *et al*.,[@b43] 2009
  96 CHC non-genotype 3 patients with advanced fibrosis treated with pegylated-IFN/RBV                                   HCV suppression was correlated with improvement in IR independent from potential confounders                                                                                        Delgado-Borrego *et al*.,[@b28] 2010
  188 patients in with different stages of HCV infection                                                                 IR, regardless of presence of T2DM, was significantly associated with HCC in patients with CHC                                                                                      Hung *et al*.,[@b44] 2010
  40 CHC genotype 1 patients enrolled in a study of danoprevir                                                           HOMA-IR improvement was correlated with a decrease in viral load                                                                                                                    Moucari *et al*.,[@b45] 2010
  92 untreated consecutive male CHC patients                                                                             IR was detected in 63 (69%) patients. IR was associated with steatosis.                                                                                                             Ahmed *et al*.,[@b46] 2011
  1,038 treatment-naive CHC patients enrolled in albinterferon alpha-2b vs. pegylated-IFNα2a study                       SVR was independently associated with significant reduction in HOMA-IR in patients with genotype 1, not in genotypes 2 or 3                                                         Thompson *et al*.,[@b47] 2012
  50 noncirrhotic, nondiabetic CHC patients (27 untreated, 23 treated with pegylated-IFN/RBV)                            IR was not strongly associated with SVR. HCV therapy may improve IR regardless of virologic response                                                                                Brandman *et al*.,[@b48] 2012
  140 CHC patients treated with pegylated-IFNα2a/RBV for 48 weeks                                                        SVR was significantly lower in the IR-HCV group compared with the non-IR-HCV. Plasma insulin levels and HOMA-IR were decreased significantly in patients with SVR                   Ziada *et al*.,[@b49] 2012
  431 CHC patients receiving pegylated-IFNα2a/RBV or pegylated-IFNα2b/RBV                                                SVR prevented development of *de novo* IR in nondiabetic patients with CHC                                                                                                          Aghemo *et al*.,[@b50] 2012
  155 anti-HCV positive patients without T2DM, hypercortisolism, thyroid disease, hyperlipidemia or infective diseases   79 (51%) patients had elevated HOMA-IR                                                                                                                                              Kiran *et al*.,[@b51] 2013
  102 nondiabetic and non-cirrhotic CHC patients (69% genotype 1)                                                        25% of subjects had IR. HCV viral load and genotype did not influence IR                                                                                                            Mukhtar *et al*.,[@b52] 2013
  30 CHC patients and 8 healthy controls underwent a fasting test                                                        9 CHC patients had elevated HOMA-IR. Total ketone body change rate was lower in CHC patients. Mitochondrial β-oxidation impairment due to HCV infection suggested                   Sato *et al*.,[@b53] 2013
  44 treatment naive patients with genotype 1 or 3                                                                       IR was found in 27 (61%) and significant steatosis in 37 (84%) patients. No difference in IR between genotypes. IR associated with higher levels of liver fibrosis and steatosis.   Péres *et al*.,[@b54] 2013

CHC, chronic hepatitis C; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HOMA, homeostatic model assessment; HIV, human immunodeficiency virus; IFNα, interferon-α; IRS, insulin receptor substrate; IR, insulin resistance; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; SVR, sustained viral response; T2DM, type 2 diabetes mellitus.

HCV and hepatic steatosis {#s3}
=========================

Hepatic steatosis was reported to be a histologic feature of non-A, non-B (NANB) hepatitis several years before hepatitis C testing was available, and it was considered common enough to be used as a diagnostic aid in the absence of serological diagnostic tests for hepatitis C.[@b55],[@b56] Steatosis occurs in 40%--86% of patients with chronic hepatitis C, and its frequency varies with genotype.[@b16]--[@b18] As already mentioned, steatosis is more common in genotype 3 infection, where it occurs in 73% of patients, while the prevalence of steatosis in patients infected with other genotypes is around 50%.[@b16]--[@b18] Infection with HCV genotype 3 is also associated with higher steatosis scores than in other genotypes, even in the absence of the metabolic risk factors associated with NAFLD, and there is a significant correlation between the degree of steatosis and the HCV RNA viral load.[@b57],[@b58] It has also been demonstrated in patients infected with HCV genotype 3 that steatosis can improve and even disappear following successful treatment with interferon (IFN) and ribavirin (RBV).[@b58] Recent studies investigating the role of a single-nucleotide polymorphism near the IL28B gene found that steatosis is less prevalent in carriers of the IL28B CC genotype, who also show less pronounced disturbances of lipid metabolism and a favorable response to IFN therapy.[@b59]

Studies investigating the association between HCV and hepatic steatosis, and their key findings, are summarized in [Table 2](#t02){ref-type="table"}.

###### The association between HCV and hepatic steatosis

  Methods/Study population                                                                                                                                                                           Findings and conclusions                                                                                                                                                                                                                Authors
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------
  240 LBS from patients with acute hepatitis A (86 patients), B (78 patients), and NANB (76 patients)                                                                                                Steatosis was found in 26% of NANB hepatitis patients compared to 10% of hepatitis A and 6% of B patients                                                                                                                               Kryger *et al*.,[@b60] 1982
  181 LBS from 94 patients with chronic NANB hepatitis                                                                                                                                               Microvesicular steatosis was found in 59% of patients and was considered a typical sign of the chronic NANB                                                                                                                             Wiese *et al*.,[@b56] 1985
  LBS from 39 patients with chronic NANB hepatitis during evaluation and follow-up                                                                                                                   Fatty metamorphosis noted in 20 (51%) patients                                                                                                                                                                                          Di Bisceglie *et al*.,[@b61] 1991
  LBS from 50 patients with CHC and 21 patients with autoimmune chronic hepatitis                                                                                                                    Steatosis was more common in patients with CHC (72% vs. 19%)                                                                                                                                                                            Bach *et al*.,[@b62] 1992
  54 LBS from 45 patients with CHC                                                                                                                                                                   Fatty change present in 29/54 (54%) specimens                                                                                                                                                                                           Scheuer *et al*.,[@b63] 1992
  LBS from 358 anti-HCV positive patients                                                                                                                                                            Steatosis was a prominent feature in patients with chronic HCV infection                                                                                                                                                                Giusti *et al*.,[@b64] 1993
  Comparison of 317 HCV and 299 HBV LBS                                                                                                                                                              Large-droplet fat droplets more likely to be seen in HCV                                                                                                                                                                                Lefkowitch *et al*.,[@b65] 1993
  LBS from 55 asymptomatic anti-HCV positive blood donors                                                                                                                                            Steatosis present in 47%                                                                                                                                                                                                                McMahon *et al*.,[@b66] 1994
  LBS from 148 patients with chronic hepatitis of which 121 (81.8%) were HCV-positive                                                                                                                Steatosis found in 60% of HCV-positive and in 52% of HCV-negative patients. No significant association between steatosis and HCV was found                                                                                              Fiore *et al*.,[@b67] 1996
  LBS from 90 patients with CHC compared according to genotype                                                                                                                                       Steatosis was more prevalent in patients with HCV genotype 3a compared to genotypes 1a or 1b                                                                                                                                            Mihm *et al*.,[@b68] 1997
  LBS from 60 CHC patients compared to 18 patients with chronic hepatitis B and 41 with nonalcoholic steatohepatitis                                                                                 Fat deposition occurred more often in patients with CHC than in chronic hepatitis B (52% versus 22%)                                                                                                                                    Czaja *et al*.,[@b69] 1998
  LBS from 43 CHC patients                                                                                                                                                                           Steatosis was observed in 21 (48.8%) patients                                                                                                                                                                                           Fujie *et al*.,[@b70] 1999
  LBS from 148 CHC untreated patients                                                                                                                                                                91 patients (61%) had steatosis of various grade                                                                                                                                                                                        Hourigan *et al*.,[@b71] 1999
  LBS from 101 HCV-infected patients without other risk factors for a fatty liver                                                                                                                    Steatosis was found in 41 (40.6%) patients. HCV genotype 3 was associated with higher steatosis scores                                                                                                                                  Rubbia-Brandt *et al*.,[@b57] 2000
  LBS from 170 CHC patients                                                                                                                                                                          Steatosis was found in 90 (52.9%) patients                                                                                                                                                                                              Ong *et al*.,[@b72] 2001
  LBS from 180 consecutive CHC patients and 41 additional subjects with a known duration of infection                                                                                                86 (48%) patients showed steatosis. Genotype 3a was associated with a higher prevalence                                                                                                                                                 Adinolfi *et al*.,[@b73] 2001
  LBS from 100 male patients with untreated noncirrhotic CHC                                                                                                                                         Hypobetalipoproteinemia and genotype 3 were associated with steatosis in CHC patients                                                                                                                                                   Serfaty *et al*.,[@b74] 2001
  Pre- and post-treatment LBS from 28 HCV genotype 1 and 34 genotype 3 patients                                                                                                                      Steatosis was initially present in 16 (57%) patients with HCV genotype 1 and 21 (62%) patients with genotype 3. Achieving SVR greatly reduced steatosis in genotype 3 patients, but not in genotype 1                                   Kumar *et al*.,[@b75] 2002
  LBS from 97 CHC patients                                                                                                                                                                           Steatosis was present in 171 patients (57.6%) with BMI and genotype 3a as independent predictors                                                                                                                                        Monto A *et al*.,[@b76] 2002
  Paired LBS from 98 CHC patients prior to antiviral treatment                                                                                                                                       41 (42%) showed signs of steatosis. Prevalence and grade of steatosis were strongly associated with HCV genotype 3                                                                                                                      Westin *et al*.,[@b77] 2002
  LBS from 124 CHC patients                                                                                                                                                                          90 (73%) specimens showed signs of steatosis. Genotype 3 was associated with increased steatosis grade                                                                                                                                  Hui *et al*.,[@b78] 2002
  Paired LBS (mean interval time of 48 months) were evaluated in 96 patients with CHC                                                                                                                Steatosis was initially found in 51 (54%) of patients. Worsening of steatosis was observed in 34% of patients, stability in 50%, and improvement in 16%                                                                                 Castéra *et al*.,[@b79] 2003
  LBS from 1,428 treatment naïve patients were assessed at baseline and 24 weeks after treatment with peginterferon or interferon α-2b and ribavirin                                                 At baseline, steatosis was present in 935 of 1428 patients (65%), including 175 of 210 patients (83%) with genotype 3 versus 760 of 1218 (62%) with other genotypes. Steatosis was associated with genotype 3, fibrosis and lower SVR   Poynard *et al*.,[@b56] 2003
  LBS from 290 CHC patients                                                                                                                                                                          135 patients (46.6%) had steatosis, and it was associated with HCV genotype 3, higher grade of necroinflammation, and higher BMI                                                                                                        Asselah *et al*.,[@b80] 2003
  LBS from 755 CHC patients                                                                                                                                                                          Steatosis was found in 315 (42%) and fibrosis in 605 patients. Steatosis was independently associated with fibrosis, genotype 3, BMI, ongoing alcohol abuse and age                                                                     Rubbia-Brandt *et al*.,[@b81] 2004
  LBS from 574 CHC patients                                                                                                                                                                          Steatosis was present in 277 (48%) of patients. Severity of steatosis was associated with BMI, HCV genotype 3, age, and duration of infection                                                                                           Patton *et al*.,[@b82] 2004
  Paired LBS (median interval of 61 months) from 135 untreated CHC patients with a METAVIR score of A1F1 or lower on first liver biopsy                                                              Steatosis was the only independent factor predictive of progression of fibrosis regardless of genotype                                                                                                                                  Fartoux *et al*.,[@b83] 2005
  LBS from two cohorts with a total of 325 genotype 1 HCV infected patients were analyzed for the presence and severity of steatosis in relation to the rs12979860 polymorphism at the IL28B locus   Steatosis was found in 67.4% (89/132) of IL28B non-CC patients compared to 39.6% (19/48) of CC patients                                                                                                                                 Tilmann *et al*.,[@b59] 2011
  LBS from 92 untreated males with CHC                                                                                                                                                               Steatosis was found in 54% of patients and was associated with IR                                                                                                                                                                       Ahmed *et al*.,[@b46] 2011
  LBS from 152 liver transplant recipients with HCV followed up for a median of 2.09 years                                                                                                           Steatosis was frequent (29.6%) in the early post-transplant period and its presence within the first year carried a higher risk of fibrosis progression                                                                                 Brandman *et al*.,[@b84] 2011
  LBS from 148 CHC patients                                                                                                                                                                          Steatosis was found in 40 patients (27%). No correlation with fibrosis or response to combined antiviral therapy was found                                                                                                              Rafi *et al*.,[@b85] 2011
  LBS from 50 HCV positive patients                                                                                                                                                                  28 (56%) patients had steatosis, and it was associated with age and triglycerides levels                                                                                                                                                Ouakaa-Kchaou *et al*.,[@b86] 2011
  LBS from 50 patients with HCV genotype 2 and 256 with HCV genotype 3                                                                                                                               Steatosis was present in 72% of patients. Advanced liver fibrosis and hepatic steatosis were more common in HCV genotype 3                                                                                                              Melo *et al*.,[@b87] 2014
  LBS from 330 patients with chronic hepatitis (66 HBV, 198 HCV, and 66 HBV-HCV co-infected)                                                                                                         Steatosis prevalence was comparable between the HBV-HCV co-infected and HCV groups (47.0% vs 49.5%, respectively). HBV group showed lowest steatosis rates (33.3%)                                                                      Zampino R *et al*.,[@b88] 2014
  110 HBV infected, 111 HCV infected and 136 NAFLD patients were evaluated using steatosis biomarkers (SteatoTest \> 0.38 as a surrogate for steatosis \> 5%)                                        Prevalence of steatosis was 21% in chronic hepatitis B, 43% in CHC and 82% in NAFLD patients                                                                                                                                            Pais *et al*.,[@b89] 2015

BMI, body mass index; CHC, chronic hepatitis C; HBV, hepatitis B virus; HCV, hepatitis C virus; LBS, liver biopsy specimens; NANB, non-A, non-B; NAFLD, non-alcoholic fatty liver disease; SVR, sustained viral response; IR, insulin resistance.

Pathogenesis of insulin resistance and steatosis in HCV infection {#s4}
=================================================================

The pathogenesis of IR and steatosis in HCV infection is a very intriguing problem, and extensive research of this topic has been undertaken. Different pathogenetic mechanisms have been proposed to explain the development of IR in HCV infected patients.[@b90]--[@b95]

*In vitro* and animal studies have greatly contributed to our understanding of both lipid and glucose metabolism alterations induced by HCV. Glucose transporter 2 (GLUT2), responsible for transporting glucose to hepatocytes, is downregulated by the HCV core protein, while the overproduction of tumor necrosis factor alpha (TNF-α), induced by HCV infection, inhibits insulin receptor substrate (IRS) and phosphatidylinositol 3 kinase (PI3K) via suppressor of cytokine signaling (SOCS)-3. These impairments of intracellular insulin signaling could block GLUT-4 activation, reducing the uptake of glucose by cells.[@b96]--[@b98]

Other cytokines besides TNF-α, such as IL-6 as well as a number of adipokines, have been shown to play a part in IR and steatosis pathogenesis of NAFLD, and evidence on their influence in HCV-induced metabolic changes continue to grow.[@b99],[@b100] HCV infection has also been suggested to cause mitochondrial dysfunction and endoplasmic reticulum impairment, while the genotype 3 HCV core protein has been shown to downregulate peroxisome proliferator activating receptor (PPARγ) and upregulate SOCS-7, leading to further impairment of insulin signaling.[@b101]--[@b103]

As for human studies, in a landmark study using liver biopsy specimens (LBS) obtained from nonobese, nondiabetic HCV-infected patients, HCV inhibited the insulin-stimulated tyrosine phosphorylation of hepatic insulin receptor substrate-1 (IRS-1), resulting in inhibition of the PI3K-Akt pathway, a key transducer of the insulin metabolic signal.[@b104],[@b105] HCV core protein was thus shown to impair hepatocyte insulin signaling by increasing cytokine production, predominantly TNF-α, activating SOCS, and inhibiting IRS through several mechanisms.

All these mechanisms are probably responsible for hepatic IR. However, there is also evidence of significant peripheral IR in HCV infection. Milner *et al*., using a hyperinsulinemic-euglycemic clamp, found no difference in hepatic glucose production and nonesterified free fatty acids suppresion with insulin between CHC patients and controls, suggesting IR is predominantly in muscles.[@b20] Vanii *et al*. approximated the contribution of peripheral IR in CHC to reach 80%.[@b19] The role of liver-derived circulating factors (hepatokines), as possible mediators of the liver-muscle crosstalk, has yet to be fully elucidated.[@b106]

The development of steatosis is also probably a result of several mechanisms. Both HCV induced and host related IR as well as metabolic factors are important for its development; it is also, however, a consequence of derangements of lipid metabolism caused directly by HCV.[@b16]

The influence of HCV on cholesterol and lipogenesis pathways of hepatocytes is a crucial part of its life cycle. HCV core protein plays a major role in the replication process by inducing accumulation of lipid droplets as well as lipogenic gene and protein activity, consequently manifesting as hepatic steatosis.[@b107] Main mechanisms of HCV-induced hepatic steatosis include promotion of lipogenesis, impairment of mitochondrial lipid oxidation, and decreased microsomal triglyceride transfer protein (MTTP) activity.[@b108],[@b109]

The activity of the HCV core protein decreases the expression and activity of the nuclear PPAR-α/γ, which, besides being strongly involved in lipid and lipoprotein metabolism, seem to have a protective effect against hepatic inflammation and fibrosis. The analysis of PPAR-α expression in LBS of 86 untreated patients with HCV and controls found it to be deeply impaired.[@b110] The HCV core protein also induces hepatic fat accumulation by activating the sterol regulatory element-binding protein-1c (SREBP-1c), a transcription factor regulating lipogenesis.[@b111] A study in transgenic mice expressing the full HCV protein repertoire showed maturational activation and nuclear translocation of SREBP-1c, resulting in increased lipogenic enzyme transcription.[@b112] The factors involved in pathogenesis of metabolic changes in HCV infection as well as clinical outcomes are shown in [Fig. 1](#f01){ref-type="fig"}.

![Pathogenetic effects and outcomes of HCV infection.](JCTH-4-066-g001){#f01}

Clinical consequences of hepatitis C associated steatosis and IR {#s5}
================================================================

The presence of both steatosis and IR in CHC may affect fibrosis and therapy outcomes as well as promote atherosclerosis and hepatic malignancy.

Liver fibrosis severity and progression are associated with hepatic steatosis and can be used as a clinically relevant parameter regarding starting and prioritizing treatment in CHC patients.[@b77],[@b82],[@b113],[@b114]

IR, independent of other factors, is significantly associated with HCC development in patients with CHC.[@b44]

Of further clinical relevance, primarily in areas where IFN-free regimens with direct-acting antivirals are not yet the standard of care, is the fact that IR has been shown to affect negatively responses to IFN treatment, effectively lowering sustained viral response (SVR) rates irrespective of genotype.[@b115]

A review by Negro lists a number of conflicting studies regarding the impact of chronic HCV infection on cardiovascular morbidity.[@b116] It is not yet clear if the reported conditions and observations, such as increased incidence of coronary artery disease, stroke rate, and carotid plaque formation, are a result of a systemic chronic inflammation, direct viral action, or a consequence of IR.

The intricacies of the pathogenesis of IR, hepatic steatosis, and metabolic syndrome are not yet fully understood, and the fact that HCV is able to induce such changes and play a part in such a complex interplay of metabolic processes means it should remain an important focus of research, even as new therapies promise to make hepatitis C an easily managable condition.

Conclusions {#s6}
===========

Many epidemiological, clinical, and experimental studies have shown that HCV infection is strongly associated with liver steatosis, IR, and the development of T2DM. Our overview of available clinical data further establishes this premise and, with very few exceptions, shows the presence and strength of this association across various groups of patients, providing a strong foothold for future consideration of this topic. The severity of hepatic steatosis in CHC arises from the combination of several host features (like visceral obesity, genetic predisposition, medication use, and alcohol consumption) and viral factors (including genotype, viral load, and gene mutations), which interfere with lipid metabolism within the hepatocytes or promote IR in the liver and peripheral tissues.

The presence and severity of HCV associated steatosis and IR impact liver fibrosis severity and progression, lower rates of response to interferon-based therapy, promote HCC development, and probably increase cardiovascular morbidity.

The recognition of the link between HCV, steatosis, and MS is important for improved patient treatment and care, and many unresolved issues make it an intriguing area of future research.
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